Size-dependent activation of CAR-T cells.

in Science immunology by Qian Xiao, Xinyan Zhang, Liqun Tu, Jian Cao, Christian S Hinrichs, Xiaolei Su

TLDR

  • The study investigates how chimeric antigen receptor (CAR)-T cells are activated by antigens. The authors propose a 'size exclusion' model explaining how antigen signals are transmitted across the plasma membrane to activate the intracellular domains of CARs. The study identifies that CAR-T activation depends on the size difference between the CAR-antigen pair and CD45. The findings suggest that the size of CAR, antigen, and CD45 can be targets for tuning CAR-T activation. The study has significant implications for the field of CAR-T cell research and clinical practice.

Abstract

As the targets of chimeric antigen receptor (CAR)-T cells expand to a variety of cancers, autoimmune diseases, viral infections, and fibrosis, there is an increasing demand for identifying new antigens and designing new CARs that can be effectively activated. However, the rational selection of antigens and the design of CARs are limited by a lack of knowledge regarding the molecular mechanism by which CARs are activated by antigens. Here, we present data supporting a "size exclusion" model explaining how antigen signals are transmitted across the plasma membrane to activate the intracellular domains of CARs. In this model, antigen engagement with CAR results in a narrow intermembrane space that physically excludes CD45, a bulky phosphatase, out of the CAR zone, thus favoring CAR phosphorylation by kinases, which further triggers downstream pathways leading to T cell activation. Aligned with this model, increasing the size of CAR extracellular domains diminished CAR-T activation both in vitro and in a mouse lymphoma model; membrane-proximal epitopes activated CAR-Ts better than membrane-distal epitopes. Moreover, increasing the size of CD45 by antibody conjugation enhanced the activation of CARs that recognize membrane-distal epitopes. Consistently, CAR-Ts expressing CD45RABC, the larger isoform, were activated to a higher level than those expressing a smaller isoform CD45RO. Together, our work revealed that CAR-T activation depends on the size difference between the CAR-antigen pair and CD45; the size of CAR, antigen, and CD45 can thus be targets for tuning CAR-T activation.

Overview

  • The study investigates the molecular mechanism by which chimeric antigen receptor (CAR)-T cells are activated by antigens. The authors propose a 'size exclusion' model explaining how antigen signals are transmitted across the plasma membrane to activate the intracellular domains of CARs. The study aims to understand the rational selection of antigens and the design of CARs for effective activation. The primary objective is to identify the molecular mechanism of CAR activation and its relationship to the size of the CAR, antigen, and CD45.

Comparative Analysis & Findings

  • The study compares the outcomes observed under different experimental conditions, including the size of CAR extracellular domains, membrane-proximal and distal epitopes, and CD45 isoforms. The results show that increasing the size of CAR extracellular domains, membrane-distal epitopes, and CD45 diminished CAR-T activation both in vitro and in a mouse lymphoma model. The study identifies that CAR-T activation depends on the size difference between the CAR-antigen pair and CD45. The findings suggest that the size of CAR, antigen, and CD45 can be targets for tuning CAR-T activation.

Implications and Future Directions

  • The study's findings have significant implications for the field of CAR-T cell research and clinical practice. The 'size exclusion' model provides insights into the molecular mechanism of CAR activation, which can inform the rational selection of antigens and the design of CARs. The study identifies that the size of CAR, antigen, and CD45 can be targets for tuning CAR-T activation. Future research could explore the use of size modulation to enhance CAR-T activation and improve clinical outcomes. The study also highlights the importance of understanding the molecular mechanisms of CAR activation for the development of more effective CAR-T cell therapies.